Deprtment of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
J Mater Sci Mater Med. 2010 May;21(5):1621-30. doi: 10.1007/s10856-010-4034-4. Epub 2010 Mar 10.
The aim of the present study was to extend the use of flurbiprofen in clinical settings by avoiding its harmful gastric effects. For this purpose, we designed the controlled release solid lipid flurbiprofen microspheres (SLFM) by emulsion congealing technique. Drug was entrapped into gastro resistant biodegradable beeswax microspheres which were prepared at different drug/beeswax ratios 1:1, 1:2 and 1:3 using gelatin and tween 20 as emulsifying agents. The effect of emulsifiers and the effect drug/beeswax ratios were studied on hydration rate, encapsulating efficiency, micromeritic properties, scanning electron microscopy (SEM), fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (X-RD) analysis and in vitro drug release at pH 1.2 for 2 h and at pH 6.8 for 10 h. SEM revealed that microspheres made with tween 20 were smooth while microspheres made with gelatin showed porous morphology, however, they were all spherical in nature. The practical yield (recovery) showed a dependence on drug-beeswax ratio and it was variable from 53 to 84%. High loading encapsulating efficiency of flurbiprofen from 8 to 94% was achieved. FTIR and DSC analysis confirmed the absence of any drug polymer interaction indicating drug stability during microencapsulation. X-RD of pure flurbiprofen shows sharp peaks, which decreases on encapsulation, indicating decrease in the crystallinity of drug in microspheres. The micromeritic studies confirmed the presence of excellent and good flow properties of microspheres. Entrapment efficiency, morphology, practical yield, hydration rate, flow properties demonstrated their dependence on the HLB value of emulsifiers and emulsifiers with higher HLB were found more appropriate for effective microencapsulation of flurbiprofen. The release kinetics followed zero order mechanism of drug release at pH 6.8. Release pattern depends on the morphology of flurbiprofen microspheres and amount of beeswax used in the microspheres preparation. The microspheres prepared with high HLB values i.e., tween 20 showed effective control of drug release from microspheres. The absence of drug release at pH 1.2 proved the suitability of beeswax for its use as a gastro resistant material.
本研究旨在通过避免其有害的胃部作用来扩展氟比洛芬在临床环境中的应用。为此,我们通过乳液凝固技术设计了控释固体脂质氟比洛芬微球(SLFM)。药物被包封到胃耐生物降解的蜂蜡微球中,这些微球是使用明胶和吐温 20 作为乳化剂,以不同的药物/蜂蜡比 1:1、1:2 和 1:3 制备的。研究了乳化剂的作用和药物/蜂蜡比的影响对水合率、包封效率、微粉特性、扫描电子显微镜(SEM)、傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、X 射线衍射(X-RD)分析以及在 pH 1.2 下 2 小时和在 pH 6.8 下 10 小时的体外药物释放的影响。SEM 表明,用吐温 20 制备的微球是光滑的,而用明胶制备的微球呈现多孔形态,但它们都是球形的。实际收率(回收率)显示出对药物/蜂蜡比的依赖性,从 53%到 84%不等。实现了氟比洛芬的高载药包封效率,从 8%到 94%不等。FTIR 和 DSC 分析证实了药物聚合物之间没有任何相互作用,表明药物在微封装过程中的稳定性。纯氟比洛芬的 X-RD 显示出尖锐的峰,在包封后减小,表明药物在微球中的结晶度降低。微粉学研究证实了微球具有良好的流动性。包封效率、形态、实际收率、水合率和流动性证明了它们对乳化剂 HLB 值的依赖性,并且发现具有较高 HLB 值的乳化剂更适合氟比洛芬的有效微封装。在 pH 6.8 时,释放动力学遵循药物释放的零级机制。释放模式取决于氟比洛芬微球的形态和微球制备中使用的蜂蜡量。用较高 HLB 值即吐温 20 制备的微球显示出对药物从微球中有效控制释放。在 pH 1.2 下没有药物释放证明了蜂蜡适合用作胃耐材料。